![Page 1: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/1.jpg)
Conventional TACE vs. drug-eluting beads
Ulf Teichgräber, MD, MBA Department of Radiology
University Hospital Jena
![Page 2: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/2.jpg)
Disclosure of conflict of interest
Speaker name: Ulf Teichgräber, MD, MBA
Potential conflicts of interest related to the presentation:
o Research grant, honoraria: Celonova (Boston Scientific)
Potential conflicts of interest not related to the presentation:
o Consulting Fees, Honoraria, Research Grants, Advisory Boards: ab medica,
Abbott Vascular, B.Braun Melsungen, Boston Scientific, Celonova, C.R.
Bard, COOK, Endoscout, GE Healthcare, iVascular, Kimal, Maquet,
Medtronic, Philips Healthcare, Siemens Heathcare, Spectranetics, W.L.Gore
o Master research agreements with Siemens Healthcare, GE Healthcare
![Page 3: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/3.jpg)
Classics
Source: Volkswagen AG
Ferdinand Porsche
Marcel Guerbet
![Page 4: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/4.jpg)
TACE with Lipiodol
Embolization o Mixture of Lipiodol mit chemotherapeutic agent 1:1
o e.g. with Doxorubicin (50mg) / Cisplatin (50mg)
Lipidol UltraFluid (480 mg Iod/ml)
ÖL Lipiodol NaCl KM
Source: own images Before TACE After TACE
DSA DSA
Fluoroscopy
Flouridated Poppy-seed oil
![Page 5: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/5.jpg)
Disadvantage
Emulsion instead of chemical binding of embolizing agent with
the chemotherapeutic substance
Source: Filipebvarela / fotolia.com
![Page 6: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/6.jpg)
TACE with Drug-loaded Beads
NH
OH OH OH OH OH O O OH O
CH3
O
O
C
NH
O
SO3-
O
NH
NHSO3
-
OOH
CH3 O
O OOHOHOHOHOH
Source: Sirtex
Dox⁺ SO₃‾
Loaded with Doxorubicin
O
O
X
O
O
NH2
OH
OHYH
OH
Z .HCl
Interactive chemical groups
Doxorubicin
o Chemical binding of the therapeutic substance
o After application
Local effect
High local drug release for 7 d
o Minimal systemic effect
![Page 7: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/7.jpg)
PRECISION V
![Page 8: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/8.jpg)
PRECISION V
• 212 patients with Child-Pugh A/B cirrhosis and large and/or multinodular, unresectable HCCs were randomized.
• Primary Endpoint TR @ 6 months.
• The DC-beads group showed higher rates of CR, OR, and DC compared with the cTACE group (27% vs. 22%, 52% vs. 44%, and 63% vs. 52%) (P=0.11).
Hypothesis of superiority of DC-beads was not met!
![Page 9: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/9.jpg)
• DC Bead was associated with improved tolerability, with a significant reduction in serious liver toxicity (P = 0.001) and a signifi-cantly lower rate of doxorubicin-related side effects (P = 0.0001).
PRECISION V
![Page 10: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/10.jpg)
Systematic Review on DC beads vs. cTACE
![Page 11: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/11.jpg)
Meta-analysis data on objective TR
Zhi-Bo Xie et al. Hepatology Research 2015; 45: 190-200
![Page 12: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/12.jpg)
• DEB-TACE was associated with a significantly higher objective tumor response rate (RR = 1.14, 95% CI = 1.01-1.29, P = 0.03) and a slightly lower incidence of adverse events.
• As a matter of fact DC beads do not provide greater survival benefit than cTACE.
Zhi-Bo Xie et al. Hepatology Research 2015; 45: 190-200
Systematic Review on DC beads vs. cTACE
![Page 13: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/13.jpg)
Embozene TANDEM®
• Capable of loading doxorubicin-HCl and irinotecan-HCl up to 50 mg/ml Microspheres.
[Dox]+
or [Iri]+
Doxo-rubicin
Irino-tecan or
Ion-exchange mechanism
DEB-TACE
non-ionic CA drug releasing via ion exchange
- Na+
![Page 14: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/14.jpg)
Embozene Microspheres
- Hyrogel Core
- Surface Nano Coating: Polyzene-
F-Shell
- Precise calibration: tight size
distribution
- highly biocompatible
- minimize inflammatory response
- Stable suspension: no aggregation,
no catheter clotting
- High elasticity and structural
integrity
Polyzene- F
Shell
Hydrogel
Core
![Page 15: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/15.jpg)
Embozene Tandem
Size 2 ml
Syringe 3 ml
Syringe
- TANDEM® Microspheres are capable of loading
doxorubicin-HCl and irinotecan-HCl up to 50 mg/ml
microspheres
- Available in three sizes
- Available in two pre filled syringe volumes
- Ideal for passage through microcatheters.
![Page 16: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/16.jpg)
Calibration
TANDEM™ 40 µm TANDEM™ 75 µm
TANDEM™ 100 µm DC-BEADS (100 – 300 µm) : 100 µm
Source: Celonova
→ Tight size distribution allows better steerable
vessel occlusion
![Page 17: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/17.jpg)
Principle
Source: Nordion/ BTG
oAim: Embolization of pre-capillary bed
oBetter and deep tumor vessel penetration
oParticle size ≤ 75 µm
Source: Nordion - BTG
![Page 18: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/18.jpg)
HCC before Embozene-TACE
Source: own images
![Page 19: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/19.jpg)
Embozene Tandem Embolization
After Embolisation
3 ml Embozene Tandem 100µm (100 mg Doxorubicin)
Before Embolization
Source: own images
![Page 20: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/20.jpg)
Follow-up @ 6 weeks
Partial Response
Source: own images
![Page 21: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/21.jpg)
Observational study on the Response Evaluation of Doxorubicin-loaded Embozene TANDEM® Microspheres with different
Particle Sizes for Transarterial Chemoembolization of the Hepatocellular Carcinoma
CT/MRT baseline
1.TACE CT/MRT 1. follow-up
2.TACE Etc. CT/MRT 2. follow up
Tumor Response
mRECIST
Assessment
Tumor Response
mRECIST
Assessment
![Page 22: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/22.jpg)
Target Lesion – mRECIST (2010)
• Consideration: every hypervascularized lesion 1 cm
• CE lesions in the arterial phase in CT or MRT vital tumor
Lencioni 2010
RECIST mRECIST
![Page 23: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/23.jpg)
Therapy Response with mRECIST
RECIST
stable mRECIST
stable
RECIST
stable mRECIST stable
(<30% reduction)
RECIST
stable mRECIST complete
response
RECIST
stable mRECIST partial
response
RECIST
stable mRECIST partial
response
RECIST
stable mRECIST partial response
![Page 24: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/24.jpg)
Patients
- 56 TANDEM® TACE in 36 patients
- In average 1,6 TACE/patient
# TACE 1 2 3 >3
Patients 17 12 3 6
![Page 25: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/25.jpg)
Results
0
10
20
30
40
50
60
CR PR SD PD
100
75
40
%
Therapy Response:
with 100 µm Tandem: 79 %
with 75 µm Tandem: 84 %
with 40 µm Tandem: 94 %
p<.05
n.s.
p<.05
![Page 26: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/26.jpg)
Injected Dose of Doxorubicin
Particle Size: 100 µm 75 µm 40 µm
Applied dose
Of Doxorubicin: 38.4 mg 43.1 mg 36.1 mg
not statistically Significant
![Page 27: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/27.jpg)
Advanced Embolization
Source: own images
![Page 28: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/28.jpg)
Quo vadis?
• GIGALIX X-ray tube – Flat emitter technology
– Small square focal spots
• New large HDR detector – Enhanced soft-tissue resolution in 3D
imaging
– High dose efficiency
Source: own images
Source: Siemens
Source: Siemens
![Page 29: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/29.jpg)
Axial plane view
Arterial phase 64-row CT Large Volume DynaCT
Source: own images
![Page 30: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/30.jpg)
Coronar plane view
Arterial phase 64-row CT Large Volume DynaCT
Source: own images
![Page 31: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/31.jpg)
Large Volume dynaCT
Source: own images
![Page 32: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/32.jpg)
Another Case Example
Baseline CE-CT Baseline CE-MRI
Source: own images
![Page 33: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/33.jpg)
Superselective Embolization
Before TACE After TACE
2 ml Embozene Tandem
40µm (50 mg Doxorubicin)
Source: own images
![Page 34: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/34.jpg)
syngo iFlow
Visualization of a complete DSA run in a color-coded single image
Before Embozene TACE After Embozene TACE
Source: own images
![Page 35: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/35.jpg)
Conclusion
Superiority of Embozene Tandem®
o Better and deep tumor vessel penetration
o Depending on embolization target selection of
particle size
o EMBOZENE TANDEM: Effective prolonged drug-
release at the embolization target
o Trend towards smaller Microsphere sizes: Aim:
Embolization of pre-capillary tumor vessels
100-300 µm
100 µm
75 µm
40 µm
Tandem
Tandem
Tandem
![Page 36: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/36.jpg)
![Page 37: Conventional TACE vs. drug-eluting beads · irinotecan-HCl up to 50 mg/ml Microspheres. [Dox]+ or [Iri]+ Doxo-rubicin Irino-or tecan Ion-exchange mechanism DEB-TACE non-ionic CA drug](https://reader036.vdocument.in/reader036/viewer/2022090905/613c8eb24c23507cb63575d3/html5/thumbnails/37.jpg)
Conventional TACE vs. drug-eluting beads
Ulf Teichgräber, MD, MBA Department of Radiology
University Hospital Jena